
|Articles|August 11, 2008
Cystoid macular oedema drug begins testing
IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
3
Oku Digital Health launches from Topcon to link eye care, primary care
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















